Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus NYSTOP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus NYSTOP.
GRISEOFULVIN, ULTRAMICROSIZE vs NYSTOP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular ions and cell death.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
Apply a thin layer to affected area 2-3 times daily or as directed. Nystatin is not absorbed systemically; topical use only.
None Documented
None Documented
9-24 hours (mean 15 hours); prolonged in liver disease.
Not applicable for systemic pharmacokinetics due to minimal absorption; local half-life on mucosal surfaces is not defined. For intravenous administration (not approved), the terminal half-life is approximately 2-4 hours, but this route is not clinically used.
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
Nystatin is not absorbed from the gastrointestinal tract or intact skin/mucous membranes; when administered topically or orally, it is excreted almost entirely in feces as unchanged drug (>99%). Less than 1% is excreted renally if ingested. No quantified biliary excretion reported.
Category D/X
Category C
Antifungal
Antifungal